First In Human Study of CX-2051 in Advanced Solid Tumors
ConditionSolid Tumor, Adult
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCytomX Therapeutics
About this trial
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
Eligibility criteria
Qualifiers
Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Measurable disease per RECIST v1.1
Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue
Disqualifiers
Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated
Known active central nervous system (CNS) involvement by malignancy
Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1
Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload
Trial design
Treatments tested in this trial
- CX-2051
- Bevacizumab
Treatment groups
160 Participants
are divided into 2 treatment groupsLocations
7Colorado
Sarah Cannon Research Institute at HealthONE80218, Denver United States
Massachusetts
Dana-Farber Cancer Institute02215, Boston United States
New York
Montefiore Medical Center10461, The Bronx United States
North Carolina
Carolina BioOncology Institute, PLLC28078, Huntersville United States
Sponsors and collaborators
CytomX Therapeutics
Lead sponsor
Source ClinicalTrials.gov